TSH Receptor Antibody Assay Developed for Grave's Disease

An automated thyroid-stimulating hormone (TSH) receptor antibody (TRAb) assay is to be developed for the differential diagnosis of Graves' disease. The TRAb test differentiates Graves' disease from toxic nodular goiters.

Graves' disease affects approximately 32 million people worldwide. As one of the most common forms of hyperthyroidism, Graves' is an autoimmune disorder characterized by the presence of stimulating TSH receptor autoantibodies found in approximately 90% of Graves' patients. Stimulating TSH receptor autoantibodies mimic the activity of TSH, leading to an elevated production of thyroid hormone. Left untreated, Graves' disease can lead to miscarriage, birth defects, thyroid eye disease, and even death.

Siemens Medical Solutions Diagnostics (Deerfield, IL, USA) announced that it signed an agreement with KreLo GmbH Medical Diagnostics (Ulm, Germany) for the rights to develop the TRAb assay and expand the thyroid immunoassay menu. Siemens will become the first in-vitro diagnostics distributor of the automated TRAb assay featuring stimulating TRAb KreLo antibodies.

Siemens Medical Solutions Diagnostics provides healthcare professionals a broad range of diagnostic products and services that are used for diagnosing medical conditions, monitoring patient therapy, and providing quality health care. Siemens' range of systems and highly responsive service are designed to improve clinical outcomes, streamline workflow, and enhance the operational efficiency of clinical laboratories worldwide.


Related Links:
Siemens Medical Solutions Diagnostics
KreLo Medical Diagnostics